Leszek Sulewski

“First, on the revivifications, can you color if you expect any spillover of these lingering into 2Q or is it now mostly resolved? And are you aware of the magnitude of these issues among your competitor?”

“So what's your confidence level for the upcoming Big Me Go readout and later in Celiac given the Sanofi and Amgen readouts? And then second on that is how competitive do you think the data has to be versus what we've seen from the dual inhibition approach of the IL-2, IL-15?”

“Can you quantify the regulatory pricing challenges you're seeing across the region? And you noted the Japanese is coming to an inflection point. Do the Oculus assets and FXOR provide net growth for the region or more of an offset from erosion due to the LOE facing there?”

“I just wanted to focus on the pilot by a similar side. So, what's the launch cadence and expected profitability profile, particularly given the U.S. channel and PBM dynamics?”